Horizon Therapeutics Public Ltd Co
HZNP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HZNP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
procysbi (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2023.
Tracking 3 pipeline candidates · 3 clinical trials for Horizon Therapeutics Public Ltd Co.
Run Horizon Therapeutics Public Ltd Co through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Horizon Therapeutics Public Ltd Co facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.75 · 2% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is Horizon Therapeutics Public Ltd Co's lead drug candidate?
Horizon Therapeutics Public Ltd Co's most advanced tracked candidate is procysbi (Approved) for nephropathic cystinosis.
Who is the CEO of Horizon Therapeutics Public Ltd Co?
Transaction Agreement is the chief executive officer of Horizon Therapeutics Public Ltd Co (HZNP).
What therapeutic areas does Horizon Therapeutics Public Ltd Co focus on?
Horizon Therapeutics Public Ltd Co develops therapies across Oncology, Immunology, Ophthalmology, Metabolic, Pain, Dermatology, Nephrology, Musculoskeletal, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.